Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
Authors
- Anthony N. Karnezis (ORCID: https://orcid.org/0000-0003-2924-1126)
- A Sukari
- Trisha M. Wise‐Draper (ORCID: https://orcid.org/0000-0002-7279-4028)
- Jennifer L. Leddon (ORCID: https://orcid.org/0000-0002-9953-0882)
- Farah Abdulla (ORCID: https://orcid.org/0000-0002-3455-7566)
- Julie McGrath (ORCID: https://orcid.org/0000-0001-8304-0355)
- Jennifer M. Johnson (ORCID: https://orcid.org/0000-0003-4548-307X)
- Chukwuemeka Ikpeazu (ORCID: https://orcid.org/0000-0003-4081-2719)
- Dalia El-Gamal
- Hira Shaikh
- Lova Sun
- Andrew Elliott
- Martina Chirra
- Dan P. Zandberg
Institutions
- University of Iowa (US)
- Thomas Jefferson University (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Phoenix Children's Hospital (US)
- UPMC Hillman Cancer Center (US)
- Caris Life Sciences (United States) (US)
- University of Iowa Health Care (US)
- Sylvester Comprehensive Cancer Center (US)
- University of California Davis Medical Center (US)
- University of Cincinnati (US)
- University of Pennsylvania (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3932
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00